Steensma DP - Search Results

1

Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes.

Steensma DP, Bejar R, Jaiswal S, Lindsley RC, Sekeres MA, Hasserjian RP, Ebert BL. Steensma DP, et al. Blood. 2015 Jul 2;126(1):9-16. doi: 10.1182/blood-2015-03-631747. Epub 2015 Apr 30. Blood. 2015. PMID: 25931582 Free PMC article.

2

Acquired alpha-thalassemia in association with myelodysplastic syndrome and other hematologic malignancies.

Steensma DP, Gibbons RJ, Higgs DR. Steensma DP, et al. Blood. 2005 Jan 15;105(2):443-52. doi: 10.1182/blood-2004-07-2792. Epub 2004 Sep 9. Blood. 2005. PMID: 15358626 Free article. Review.

3

The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and myelodysplastic syndromes.

Steensma DP, Dewald GW, Lasho TL, Powell HL, McClure RF, Levine RL, Gilliland DG, Tefferi A. Steensma DP, et al. Blood. 2005 Aug 15;106(4):1207-9. doi: 10.1182/blood-2005-03-1183. Epub 2005 Apr 28. Blood. 2005. PMID: 15860661 Free PMC article.

4

Defining prior therapy in myelodysplastic syndromes and criteria for relapsed and refractory disease: implications for clinical trial design and enrollment.

Sekeres MA, Steensma DP. Sekeres MA, et al. Among authors: steensma dp. Blood. 2009 Sep 24;114(13):2575-80. doi: 10.1182/blood-2009-06-228114. Epub 2009 Jul 15. Blood. 2009. PMID: 19605847 Free PMC article. Review.

5

The changing classification of myelodysplastic syndromes: what's in a name?

Steensma DP. Steensma DP. Hematology Am Soc Hematol Educ Program. 2009:645-55. doi: 10.1182/asheducation-2009.1.645. Hematology Am Soc Hematol Educ Program. 2009. PMID: 20008250 Review.

6

The molecular pathogenesis of myelodysplastic syndromes.

Davids MS, Steensma DP. Davids MS, et al. Among authors: steensma dp. Cancer Biol Ther. 2010 Aug 15;10(4):309-19. doi: 10.4161/cbt.10.4.12612. Epub 2010 Aug 5. Cancer Biol Ther. 2010. PMID: 20592488 Review.

7

The role of iron chelation therapy for patients with myelodysplastic syndromes.

Steensma DP. Steensma DP. J Natl Compr Canc Netw. 2011 Jan;9(1):65-75. doi: 10.6004/jnccn.2011.0007. J Natl Compr Canc Netw. 2011. PMID: 21233245 Review.

8

Perceptions of disease state, treatment outcomes, and prognosis among patients with myelodysplastic syndromes: results from an internet-based survey.

Sekeres MA, Maciejewski JP, List AF, Steensma DP, Artz A, Swern AS, Scribner P, Huber J, Stone R. Sekeres MA, et al. Among authors: steensma dp. Oncologist. 2011;16(6):904-11. doi: 10.1634/theoncologist.2010-0199. Epub 2011 Apr 8. Oncologist. 2011. PMID: 21478277 Free PMC article.

9

Lenalidomide in AML: del(5q) or who?

Steensma DP, Stone RM. Steensma DP, et al. Blood. 2011 Jul 21;118(3):481-2. doi: 10.1182/blood-2011-05-354324. Blood. 2011. PMID: 21778344 Free article. No abstract available.

10

A piece of my mind. The road warriors.

Sekeres MA, Steensma DP. Sekeres MA, et al. Among authors: steensma dp. JAMA. 2011 Aug 24;306(8):805-6. doi: 10.1001/jama.2011.1191. JAMA. 2011. PMID: 21862735 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

493 results

Search Page